Moreover, in the circulation of cancer patients, the peripheral blood neutrophil-to-lymphocyte ratio (NLR) increases, making NLR a focal point in current research for assessing tumor prognosis due to its evaluability through blood tests.274–276 The NLR is a well-defined biomarker associated with poor prognosis in patients with tumors such as glioblastoma,274 NSCLC,275 and CRC.276 In circulation, neutrophils can secrete tumor-promoting factors such as IL-6, associated with poor prognosis. The gene discussed is IL6; the disease is neoplasm.